| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 862.7 | 784.5 |
| Gross profit | 334.1 | 274.0 |
| Profit before tax | 15.1 | -5.2 |
| Net income | -21.7 | 2.4 |
| EPS (diluted, $ a share) | $-0.06 | $0.01 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +10.0% |
|---|---|
| Gross margin | 38.7% |
| Operating margin | 11.1% |
10-Q filed with the SEC, NASDAQ: AMRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Amneal Pharmaceuticals, Inc.: key numbers
- Share price
- $21.12Close, Nov 17
- Market cap
- $7.36B
- Shares outstanding
- 348.41MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Amneal Pharmaceuticals, Inc.
All →Amneal Pharmaceuticals Financial Results
Amneal Pharmaceuticals reported Q3 2026 net revenue of $863 million, a 10% increase year-over-year, driven by strong growth in biosimilars and specialty products. Despite the revenue growth, the company posted a GAAP net loss of $22 million due to acquisition and integration costs related to Kashiv. Consequently, Amneal raised its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS.
- Term
- Q3 2026
“Amneal delivered another quarter of strong, broad-based performance, enabling us to increase our 2026 guidance once more. As we prepare to enter 2027, our financial performance is accelerating driven by a number of key catalysts and new launches, including Women’s Health patches, biosimilars, injectables such as lanreotide, CREXONT®, and BREKIYA® autoinjector.”
Chirag and Chintu Patel, Co-Founders and Co-Chief Executive Officers
Amneal Pharmaceuticals M&A Deal with Kashiv BioSciences, LLC
Amneal Pharmaceuticals filed an amendment to its previous 8-K to provide required historical financial statements and pro forma financial information following its completed acquisition of Kashiv BioSciences, LLC. The acquisition was originally completed on August 10, 2026, pursuant to a Membership Interest Purchase Agreement dated April 21, 2026.
- Counterparty
- Kashiv BioSciences, LLC